Table 2.
Thirty day outcomes among patients with acute myocardial infarction surviving to thirty-day follow-up, northern Tanzania, 2019 (N=85)
| All surviving patients N=85* | Number of Participants | (%) |
|---|---|---|
| Symptom Progression at 30 days | ||
| Resolved | 14 | 16.5% |
| Improved | 53 | 63.4% |
| Worsened or unchanged | 18 | 21.2% |
| Received a prescription at hospital discharge | 81 | 95.3% |
| Reports taking medications as prescribed (N=81) | 75 | 92.6% |
| Reports taking aspirin | 4 | 4.7% |
| Reports taking dual anti-platelet therapy | 0 | 0% |
| Reports taking beta-blocker | 1 | 1.2% |
| Reports taking angiotension-converting enzyme (ACE) inhibitor or angiotension receptor blocker (ARB) | 3 | 3.5% |
| Reports taking statin | 1 | 1.2% |
| Identified acute MI as their diagnosis | 7 | 8.2% |
| Feels they understand their treatment | 64 | 75.3% |
| Given 30-day follow-up appointment | 36 | 42.4% |
| Attended follow-up clinic appointment (N=36) | 23 | 63.9% |
| Unscheduled hospitalizations for recurrent chest pain/shortness of breath after discharge | 17 | 20.0% |
*
2 lost to follow up
MI: myocardial infarction